Global acceptance of COVID-19 vaccine among persons with diabetes: A systematic review and meta-analysis

Abstract

Aim: This review aimed to estimate the level of acceptance of COVID-19 vaccine among persons with diabetes. Methods: A systematic search was conducted on PubMed, MEDLINE, Embase, and CINAHL to identify relevant studies for this review. A random-effects meta-analysis was performed to generate an overall estimate of vaccine acceptance. The I 2 statistic was used to quantify the degree of variation across studies, and subgroup analysis was conducted to identify the sources of heterogeneity. The review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). Results: This review included 18 studies involving 11,292 diabetes patients. The pooled prevalence of COVID-19 vaccine acceptance among persons with diabetes was 76.1% (95% CI: 66.7%–83.5%). The pooled prevalence across the continent ranged from 68.9% (95% CI: 47.8%–84.3%) in Asia to 82.1% (95% CI: 80.2%–83.8%) in Europe. Barriers to vaccine acceptance included misinformation, lack of information, mistrust, health concerns, and external influences. Conclusion: The barriers to vaccine acceptance identified in this review, could inform the formulation of health policies and public health interventions that are specifically tailored to address the needs of persons with diabetes.